Scilex Holding Company Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Scilex Holding Company (SCLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $47.30 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-04-10
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $28.10K.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $10.40K.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-03-31 was $8.80K.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $47.30K, a 95.70% decline from fiscal 2023.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $1.10M, a 266.67% increase from fiscal 2022.
- Scilex Holding Company share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $300.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $28.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $28.10K derived: sum of 2 quarters · filed 2026-04-10 | $38.50K derived: sum of 3 quarters · filed 2026-04-10 | $47.30K 10-K · filed 2026-04-10 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $10.40K derived: sum of 2 quarters · filed 2025-01-17 | $19.20K 10-Q · filed 2025-01-17 | $19.20K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $10.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $19.20K 10-Q · filed 2024-08-13 | $19.20K derived: sum of 3 quarters · filed 2025-03-31 | $319.20K derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $8.80K 10-Q · filed 2024-05-13 | $8.80K derived: sum of 2 quarters · filed 2025-03-31 | $308.80K derived: sum of 3 quarters · filed 2025-03-31 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $300.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.10M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.10M 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $300.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |